A Study to Evaluate AZD7760 Safety and Pharmacokinetics in Healthy Adults (Phase I) and Adults With End-stage Kidney Disease on Hemodialysis With a Central Venous Catheter (Phase IIa)
← catalyst calendarNCT06749457 · readout in 226 d
Sponsored by AstraZeneca (industry) · AZN — their whole pipeline →. With Parexel.
Phase
Phase 1/2
Status
Recruiting
Study type
Interventional
Design
Randomized · Quadruple · Prevention
Enrollment
231estimated
Sites
44
Country
United States
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2024-12-30 | actual | When the study began enrolling |
| Primary completion | 2027-04-02 | estimated | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | 2028-01-07 | estimated | The whole study's end, after follow-up |
| First posted | 2024-12-27 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2026-08-14 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Condition
- Staphylococcus Aureus
Interventions
- Drug: AZD7760
- Other: Placebo
Primary outcomes
what the primary-completion date above is the date OFPhase I: Occurence of adverse events (AEs)
measured Day 1 to Day 181
Phase I: Occurence of medically-attended adverse events (MAAEs), serious adverse events (SAEs), and adverse events of special interest (AESIs)
measured Day 1 to Day 361
Phase IIa: Occurrence of AEs, MAAEs, SAEs, and AESIs
measured Day 1 to Day 181
Permalink · AZN's whole pipeline · Catalyst calendar · Every registered study · What changed